Navigation Links
New U.S. Patent Issued to Dyadic International
Date:4/27/2011

JUPITER, Fla., April 27, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,923,236 entitled, "Fungal Enzymes" by the United States Patent and Trademark Office ("USPTO").

The inventions embodied by this patent relate to the use of and methods for producing novel enzymes and their combinations to convert lignocellulosic biomass into fermentable sugars. These unique enzymes degrade lignocellulosic sugars including those that provide a synergistic release of sugars from plant biomass.

The inventions also relate to methods of using novel enzymes and their combinations in a variety of other processes including the simultaneous production of organic substances such as alcohol, ethanol, amino and organic acids as well as other organic substances. Additional claims are directed to a variety of pulp and paper manufacturing processes such as biorefining, deinking and bleaching as well as for use in the treatment of waste streams and in textile and detergent processes. These enzymes were isolated from Dyadic's patented and proprietary C1 fungus and additionally identified through the genome annotation project conducted by Dyadic in conjunction with Scripps Florida.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "This patent provides Dyadic with additional protection in the use of unique enzymes generated from Dyadic's C1 platform technology to unlock the economic power of converting plentiful feedstocks of plant materials into sugars that can be fermented into chemicals, plastics, and fuels including ethanol, as a substitute for petroleum.  These novel enzymes may also be applied in other industries in which Dyadic competes such as pulp and paper, waste treatment and textiles."

The newly issued patent is accessible on the USPTO's website at www.uspto.gov or on Dyadic's website at www.dyadic.com.

This patent is the tenth U.S. patent issued to Dyadic adding to its portfolio of 74 international patents and more than 33 pending patent applications worldwide which cover various features of Dyadic's proprietary technologies.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Patent and Trademark Office (USPTO) Issues QRxPharma a New Patent for MoxDuo® IR; Extends Patent Coverage to 2029
2. Cellectis Receives Payment for License to Homologous Recombination Patents
3. ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China
4. Grunenthal Group Acquires Pain Patent Portfolio From Nectid, Inc.
5. ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air
6. ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction
7. Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis
8. Fuisz Pharma Announces Patented Communication of Analyte Information Between Microchip Containing Smart Tablet and a Body Fluid Analyzer
9. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
10. Reportlinker Adds Amphotericin B - Comprehensive patent search
11. Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... published their findings on what they believe could be a new and helpful ... the new research. Click here to read it now. , Biomarkers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):